表紙
市場調査レポート

ペプチド治療薬の世界市場 (2016〜2020年)

Global Peptide Therapeutics Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 317311
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ペプチド治療薬の世界市場 (2016〜2020年) Global Peptide Therapeutics Market 2016-2020
出版日: 2016年03月04日 ページ情報: 英文 81 Pages
概要

ペプチドは有機化合物の一種で、ペプチド結合により科学的に結び合わされたアミノ酸で構成されています。生物活性成分の中でも最も潜在力の高い物質で、ヒトの生理的プロセスを促進・制御・維持するために利用されています。しかし、ペプチドは非常に不安定で、細胞膜を通過できないため、治療薬として使用するには常に困難を伴います。また、合成過程の難しさやコストの高さにも対処する必要があります。そうした困難を乗り越えて、現在では80種類以上の製品が上市され、慢性疾患の治療に使われています。世界のペプチド治療薬市場は、2016年〜2020年の期間中、7.92%のCAGR (複合年間成長率) が見込まれています。

当レポートでは、世界のペプチド治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブ・サマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要
  • 大手ベンダーの主要製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略

第5章 ペプチドの概要

  • ペプチドの合成方法
  • ペプチドの最適化
  • ペプチドの安定化

第6章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第7章 投与経路別の市場区分

  • 非経口投与
  • 経口投与
  • 経肺投与
  • 経粘膜投与

第8章 薬剤クラス別の市場区分

  • ソマトスタチン
  • バソプレッシン
  • カルシトニン
  • LHRH (黄体形成ホルモン (LH) 放出ホルモン)
  • グルカゴンとその類似体
  • インスリン
  • その他

第9章 合成技術別の市場区分

  • 液相ペプチド合成
  • 固相ペプチド合成
  • ハイブリッド合成

第10章 地域区分

  • 世界のペプチド治療薬市場:地域別の詳細動向 (2015〜2020年)
  • 南北アメリカ市場
  • 欧州・中東・アフリカ諸国 (EMEA) 市場
  • アジア太平洋地域市場

第11章 市場促進要因

  • 患者人口の増加
  • ペプチド合成技術の進歩
  • 将来有望なパイプライン製品
  • 医療上のアンメットニーズ
  • 医療費支出の増大

第12章 促進要因の影響力

第13章 市場の課題

  • 治療費の高さ
  • 副作用
  • 厳格な規制の遵守
  • 市場競争の激化

第14章 促進要因・課題の影響力

第15章 市場の動向

  • 人気の拡大
  • 未開拓市場への関心の移行
  • 受託製造
  • 一般的な認知度の上昇

第16章 ベンダー環境

  • 競争シナリオ
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • 武田薬品工業
  • Teva Pharmaceuticals
  • その他の有力ベンダー

第17章 付録

  • 略語集

第18章 Technavioについて

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR8630

About Peptide Therapeutics

Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.

Technavio's analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals

Other Prominent Vendors

  • AbbVie
  • Advanced Accelerator Applications
  • Akashi Therapeutics
  • Amgen
  • Anthera Pharmaceuticals
  • AstraZeneca
  • Bachem
  • Bristol-Myers Squibb
  • Cardiorentis
  • Corden Pharma International
  • Debiopharm
  • Derma Sciences
  • GlaxoSmithKline
  • Hanmi Pharmaceutical
  • Insmed
  • Ipsen
  • Johnson & Johnson
  • Lonza
  • Mallinckrodt
  • MolMed
  • Merck
  • Novartis
  • Nymox Pharmaceutical
  • Par Pharmaceuticals
  • PeptiDream
  • Polypeptide Group
  • Radius Health
  • Repligen
  • Roche
  • SciClone
  • Shire
  • The Medicines Company
  • Transition Therapeutics
  • X-Gen Pharmaceuticals
  • Zealand Pharma
  • Zydus Cadila

Market driver

  • Increase in patient population
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Shifting focus toward untapped markets
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of peptides

  • Peptide synthesis
  • Optimization of peptides
  • Stabilization of peptides
  • PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation based on route of administration

  • Parenteral
  • Oral
  • Pulmonary
  • Mucosal

PART 08: Market segmentation by drug class

  • Somatostatins
  • Vasopressin
  • Calcitonins
  • Luteinizing hormone (LH)-releasing hormone (LHRH)
  • Glucagon and analogs
  • Insulins
  • Other

PART 09: Market segmentation by synthesis technology

  • Liquid-phase peptide synthesis
  • Solid-phase peptide synthesis
  • Hybrid peptide synthesis

PART 10: Geographical segmentation

  • Global peptide therapeutics market segmentation by geography 2015-2020
  • Peptide therapeutics market in Americas
  • Peptide therapeutics market in EMEA
  • Peptide therapeutics market in APAC

PART 11: Market drivers

  • Increase in patient population
  • Advances in peptide synthesis technology
  • Promising pipeline
  • Unmet medical needs
  • Increase in healthcare spending

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Adverse side effects
  • Stringent regulatory compliances
  • Intense market competition

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Growing popularity
  • Shifting focus toward untapped markets
  • Contract manufacturing
  • Increase in public awareness

PART 16: Vendor landscape

  • Competitive scenario
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: SWOT analysis: Peptide therapeutics
  • Exhibit 03: Steps involved in peptide synthesis
  • Exhibit 04: Optimization of peptide synthesis
  • Exhibit 05: Methods used to stabilize peptides
  • Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
  • Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
  • Exhibit 10: Global peptide therapeutics market segmentation by drug class
  • Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
  • Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
  • Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 18: Impact of drivers
  • Exhibit 19: Impact of drivers and challenges
  • Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
  • Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
  • Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
  • Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
  • Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
  • Exhibit 25: Eli Lilly: Key takeaways
  • Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
  • Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
  • Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
  • Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
  • Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
  • Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
  • Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
  • Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
  • Exhibit 34: Novo Nordisk: Key takeaways
  • Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
  • Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
  • Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
  • Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
  • Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
  • Exhibit 40: Sanofi: Key takeaways
  • Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
  • Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
  • Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
  • Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
  • Exhibit 45: Takeda Pharmaceutical: Key takeaways
  • Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
  • Exhibit 47: Teva Pharmaceuticals: Key takeaways
Back to Top